ERBB2 and carcinoma: Consistently, when we focused only on activating mutations in the PI3K-AKT pathway, regardless of the HER2 status, we found that the activation of biological pathways in mutant carcinomas was stronger and seemed to be more efficient than the activation due to HER2 amplification/hyperexpression alone.